Clinical trials: Significant Prostate Cancer, active
Prostate Cancer
Sequential Imaging of Suspicion of Prostate Cancer Reducing Overdiagnosis and Unnecessary Biopsy With Timely Diagnosis of Significant Cancer
The goal of this clinical trial is to evaluate the safety and effectiveness of a novel diagnostic strategy for prostate cancer, in which men with a moderate risk of prostate cancer are monitored using PSA and MRI instead of…
- Trial name
- SPROUT (NCT07180381)
- Testing
- PSA and MRI-monitoring
- Where
- 7 sites in Netherlands
- Volunteers
- 503 people
- Sponsor
- St. Antonius Hospital
Clinically Significant Prostate Cancer
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
- Trial name
- NCT07492927
- Where
- 10 sites in United States, China
- Volunteers
- 1,700 people
- Sponsor
- Xijing Hospital
Prostate Cancer
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
The purpose of this study is to find out how best to detect clinically significant lesions of prostate cancer by using micro-ultrasound technology (ExactVu) and by multiparametric magnetic-resonance imaging (mpMRI).
- Trial name
- OU-SCC-PROBX (NCT05471128)
- Testing
- Standard of Care Biopsy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Oklahoma
Prostatic Neoplasm of Uncertain Behavior
Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer
Study Goal: The purpose of this clinical trial is to determine if combining high-frequency micro-ultrasound with multiparametric MRI biopsy and a systematic biopsy can better detect clinically significant prostate cancer compared…
- Trial name
- Biopsy29 (NCT06579911)
- Testing
- High-frequency micro-ultrasound target biopsy, conventional Multiparametric MRT target biopsy
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken
Significant Prostate Cancer
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
Through a better understanding of the biology of significant (lethal) prostate cancer, we hope to develop new markers/targets from urine metabolomics for more effective screening and prevention of significant prostate cancer.
- Trial name
- NCT03237702
- Testing
- Multi-Carotenoids
- Where
- Taiwan
- Volunteers
- 2,000 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis
Prostate biopsy usually combines magnetic resonance imaging/ultrasound (MRI/US) cognitive fusion targeted biopsy with systematic biopsy.
- Trial name
- IBIS-PC (NCT07795723)
- Testing
- MRI/US Cognitive Fusion Targeted Biopsy Plus Ipsilateral Systematic Biopsy, MRI/US Cognitive Fusion Targeted Biopsy Plus Bilateral Systematic Biopsy
- Where
- China
- Volunteers
- 454 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer (Diagnosis), Prostate Cancer
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
Prostate cancer diagnosis based on systematic or MRI-targeted biopsy is associated with substantial overdiagnosis and unnecessary invasive procedures.
- Trial name
- INSIGHT-PCa (NCT07398690)
- Testing
- Diagnostic Procedure
- Where
- South Korea
- Volunteers
- 1,432 people
- Sponsor
- In Gab Jeong, MD
Prostate Cancer
European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection
The goal of this clinical trial is to learn if a new ultrasound-based imaging method (PCaVision) can accurately detect clinically significant prostate cancer in adult men (18 years and older) who are either undergoing initial…
- Trial name
- PCaVISTA (NCT06935487)
- Testing
- transrectal ultrasound of prostate (TRUS) with AI software algorithm, MRI prostate
- Where
- 10 sites in France, Germany and 4 more
- Volunteers
- 806 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Prostate Cancer
Artificial Intelligence Software (Prostate Intelligence) for Detecting Clinically Significant Prostate Cancer on MRI
The goal of this study is to learn how accurately an artificial intelligence (AI) software called Prostate Intelligence (Pi) detects clinically significant prostate cancer on prostate MRI in adults with a prostate gland who are…
- Trial name
- RADAR (NCT07875491)
- Testing
- AI-based prostate MRI analysis software
- Where
- Italy
- Volunteers
- 226 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymphoma, Advanced Prostate Cancer
Whole Body MRI in Oncology
Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice.
- Conditions
- Lymphoma, Advanced Prostate Cancer, Advanced Breast Cancer, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ONCO-MRI (NCT06895291)
- Testing
- Whole Body-Magnetic Resonance Imaging (WB-MRI)
- Where
- 3 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Inherited Cancer Syndrome, Prostate Cancer
Improving Care After Inherited Cancer Testing
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results for individuals with a documented…
- Conditions
- Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer
- Trial name
- IMPACT (NCT04763915)
- Testing
- Correlative Studies (Survey), Correlative Studies (Interview), GeneSHARE
- Where
- United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Prostate
POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions
The goal of this study to determine if using the (18)F-rhPSMA-7.3 PET-CT scan can improve the ability to spot serious prostate cancer in patients who have uncertain MRI results.
- Trial name
- NCT07220720
- Testing
- Flotufolastat F 18
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Treatment-naive Prostate Cancer, Suspected Prostate Cancer
Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer
Brief Summary This prospective, multicenter study evaluates whether delayed PSMA PET imaging improves diagnostic efficacy for detecting clinically significant prostate cancer (Gleason score ≥7) compared with standard imaging in…
- Conditions
- Treatment-naive Prostate Cancer, Suspected Prostate Cancer, Molecular Imaging
- Trial name
- DEPICT (NCT07531329)
- Testing
- [⁶⁸Ga]Ga-PSMA PET/CT with Delayed Pelvic PET-Only Acquisition
- Where
- 9 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Xijing Hospital
Prostate Cancer, Active Surveillance for Prostate Cancer
Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance
Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease.
- Conditions
- Prostate Cancer, Active Surveillance for Prostate Cancer, Imaging Techniques
- Trial name
- MUS-AS (NCT07386171)
- Testing
- Micro-Ultrasound (mUS)
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Prostate Cancer
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
The percentage of malignant prostate tumors detected very early is constantly increasing and the number of well differentiated tumors, with small volume and low risk of progression increases.
- Trial name
- HIFUSA (NCT03531099)
- Testing
- treatment with focal HIFU, PSA dosage, MRI
- Where
- 14 sites in France
- Volunteers
- 108 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI
This clinical trial will evaluate PSMA PET additive value for significant prostate cancer (sPCa) diagnosis in men with negative/equivocal MRI
- Trial name
- PRIMARY2 (NCT05154162)
- Testing
- PSMA PET/CT, Transperineal template prostate biopsy, Transperineal targeted prostate biopsy
- Where
- 6 sites in Australia
- Volunteers
- 660 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Carcinoma
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
This early phase I trial studies how well an image-guided prostate biopsy using the imaging agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a positron emission tomography/computed tomography (PET/CT) scan works in…
- Trial name
- NCT05160597
- Testing
- Biopsy of Prostate, Gallium Ga 68 Gozetotide, Transrectal Ultrasonography Guided Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Low Risk Prostate Cancer, Clinically Significant Prostate Cancer
Study of PSMA PET/CT Imaging to Help Select Men With Low-Risk Prostate Cancer for Active Surveillance
This is a multicenter, prospective diagnostic accuracy study evaluating the Istanbul PSMA PET/CT Criteria (IPPC) for selecting patients with biopsy-confirmed low-risk prostate cancer (ISUP Grade 1) for active surveillance (AS).
- Trial name
- I-SELECT (NCT07168616)
- Testing
- Ga-68 PSMA11 PET/CT
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 201 people
- Sponsor
- Istanbul University - Cerrahpasa
Health Status Unknown, Elevated PSA
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
This randomized phase II trial studies how well systematic random biopsy or magnetic resonance imaging (MRI)-ultrasound image (US) fusion biopsy work in diagnosing prostate cancer in patients with elevated prostate specific…
- Trial name
- NCT03234556
- Testing
- Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Where
- 4 sites in United States
- Volunteers
- 288 people
- Sponsor
- University of Southern California
High-risk Prostate Cancer, PSMA PET
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer
This prospective, multicenter study aims to evaluate the clinical utility of serial PSMA PET for therapy monitoring in patients with newly diagnosed clinically significant prostate cancer.
- Conditions
- High-risk Prostate Cancer, PSMA PET, Treatment Response, Therapy Monitoring
- Trial name
- PSMA-TM (NCT07553780)
- Where
- 9 sites in China
- Volunteers
- 110 people
- Sponsor
- Xijing Hospital